---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-24-000221"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:41:25.880256+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B

## Summary
- GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.
- FY 2024 product revenue guidance raised to $10.8-10.9B from $10.65-10.85B.
- PDUFA dates: vanzacaftor triple Jan 2, 2025; suzetrigine Jan 30, 2025; both Priority Review.
- Three programs advanced to Phase 3: suzetrigine in DPN, povetacicept in IgAN, VX-880 in T1D.
- CASGEVY revenue from first infused patient; 45 ATCs activated globally.

## SEC filing metadata
- accession: 0000875320-24-000221
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/0000875320-24-000221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/vrtx-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-24-000221
- JSON: https://secwatch.observer/filing/0000875320-24-000221.json
- Plain text: https://secwatch.observer/filing/0000875320-24-000221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.